Icis
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
If Icis is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients. · J Immunother Cancer · 2026-09-02
- Immune Checkpoint Inhibitor Resistance in Rectal Adenocarcinoma Containing a Mismatch Repair Deficiency Component: A Case Report. · Cancer Diagn Progn · 2026-09-01
- Pan-cancer single-cell atlas of immunotherapy response identifies ZNF385A as a regulator of immune evasion in small cell lung cancer. · Biochim Biophys Acta Mol Basis Dis · 2026-08-29
- The dual roles of lysine-specific demethylase 1 (KDM1A/LSD1) in the modulation of tumor immune microenvironment and its inhibitors in colorectal cancer. · J Mol Med (Berl) · 2026-08-24
- Impact of immunotherapy in the treatment of early-stage non-small lung cancer, melanoma, and colorectal cancer. · Immunotherapy · 2026-08-24
- Body mass index and dyslipidemia influence responses to anti-PD-1 immunotherapy in colorectal cancer. · Ann Med · 2026-08-24
What the reporting says
It shows up alongside Immunotherapy (21), Colorectal Cancer (14), Lung Cancer (8).
Two steps out: ASCO (through Immunotherapy, 21 shared stories on the weaker link); FDA (through Immunotherapy, 21 shared stories on the weaker link); KRAS (through Immunotherapy, 21 shared stories on the weaker link); Merck (through Immunotherapy, 21 shared stories on the weaker link).
Tracked since Jan 1, with coverage on 14 separate days — concentrated in Pubmed Targeted and Oncology.